Table 3.

Incidence table adverse events (AE) to COVID vaccine in patients affected by thymic epithelial tumours.

	Gradea		Onsetb			Durationc			Systemic pharmacological intervention required
	G1	G2	<7 day	8–14 days	>15 days	1–3 days	4–7 days	>7 days
Fever	8 (2)	2 (1)	10 (3)	0 (0)	0 (0)	9 (3)	1 (0)	0 (0)	6 (3)
Fatigue	27 (10)	1 (0)	26 (8)	1 (1)	1 (1)	22 (8)	2 (0)	4 (2)	2 (1)
Headache	7 (2)	1 (0)	8 (2)	0 (0)	0 (0)	7 (2)	1 (0)	0 (0)	0 (0)
Chills	14 (6)	0 (0)	14 (6)	0 (0)	0 (0)	13 (6)	1 (0)	0 (0)	2 (1)
Muscle pain	19 (5)	2 (1)	21 (6)	0 (0)	0 (0)	17 (6)	4 (0)	0 (0)	3 (2)
Joint pain	8 (3)	1 (0)	9 (3)	0 (0)	0 (0)	5 (3)	4 (0)	0 (0)	2 (0)
Vomiting	2 (1)	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	1 (0)
Diarrhoea	2 (0)	1 (0)	3 (0)	0 (0)	0 (0)	2 (0)	0 (0)	0 (0)	0 (0)
Other	7 (0)	1 (0)	7 (0)	1 (0)	0 (0)	6 (0)	1 (0)	1 (0)	1 (0)

Note: ‘Muscle pain’ refers to new or worsening muscle pain; ‘joint pain’ refers to new or worsening joint pain. Results for patients affected by thymic carcinoma are reported in brackets.

Keys:

^aGrade of AE, according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

^bDays from vaccination to onset of AE.

^cDuration of AE.